Indivior PLC

Indivior PLC is a global leader in the field of addiction treatment, dedicated to helping individuals overcome substance use disorders. Founded in 2014 as a spin-off from Reckitt Benckiser, the company has established itself as a pioneer in developing innovative therapies for opioid dependence and other addictions.

With a strong commitment to research and development, Indivior focuses on creating effective medications that improve patient outcomes and support recovery. The company’s flagship product, Suboxone, is widely recognized for its role in treating opioid addiction, providing patients with a pathway to recovery.

Indivior operates in over 30 countries, ensuring that its life-saving treatments are accessible to those in need. The company collaborates with healthcare professionals, governments, and advocacy groups to raise awareness about addiction and promote best practices in treatment.

In addition to its core focus on addiction, Indivior is also exploring new therapeutic areas, aiming to expand its portfolio and address unmet medical needs. The company is guided by a vision of a world where every individual struggling with addiction can find hope and healing.

Indivior’s corporate social responsibility initiatives reflect its commitment to making a positive impact on society. Through various programs, the company supports education, prevention, and community engagement efforts aimed at reducing the stigma associated with addiction.

As a publicly traded company listed on the London Stock Exchange, Indivior is committed to transparency and accountability, ensuring that it operates with integrity and adheres to the highest ethical standards.

Overall, Indivior PLC stands at the forefront of addiction treatment, driven by a mission to transform lives and foster recovery through innovative solutions.